Drug Trial Radar · NCT02621892
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Last checked: Nov 19, 2026Latest source record: Apr 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
606
Actual
Start
Oct 2015
Primary completion
Mar 2017
Study completion Apr 2017
Sponsor
- Lead sponsor
- ArdelyxIndustry
- Sponsor type
- Industry
- First posted
- Dec 4, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 3, 12-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as defined by the ROME III criteria and who have active disease as determined after a two-week screening period. Subjects who qualify and are randomized into the study will either receive 50mg BID of tenapanor or placebo BID for 12 week treatment period and then undergo a 4 week placebo controlled randomized withdrawal.
Conditions
- Constipation Predominant Irritable Bowel Syndrome
Interventions
TenapanorDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- 6 of 12 Week Overall Responder RateTime frame: 12 weeks
Locations
111 sites in 1 country. Site status is shown where the registry gives one.
Ardelyx Investigative Site 149
Birmingham, Alabama
Ardelyx Investigative Site 114
Birmingham, Alabama
Ardelyx Investigative Site 103
Huntsville, Alabama
Ardelyx Investigative Site 100
Huntsville, Alabama
Ardelyx Investigative Site 145
Chandler, Arizona
Ardelyx Investigative Site 210
Phoenix, Arizona
Ardelyx Investigative Site 296
Phoenix, Arizona
Ardelyx Investigative Site 277
Tempe, Arizona
Ardelyx Investigative Site 269
Tucson, Arizona
Ardelyx Investigative Site 187
Tucson, Arizona
Ardelyx Investigative Site 199
Tucson, Arizona
Ardelyx Investigative Site 140
Harrisburg, Arkansas
Ardelyx Investigative Site 274
Little Rock, Arkansas
Ardelyx Investigative Site 161
Little Rock, Arkansas
Ardelyx Investigative Site 122
Little Rock, Arkansas
Ardelyx Investigative Site 129
North Little Rock, Arkansas
Ardelyx Investigative Site 105
Canoga Park, California
Ardelyx Investigative Site 143
Chula Vista, California
Ardelyx Investigative Site 146
Encino, California
Ardelyx Investigative Site 147
Encino, California
Ardelyx Investigative Site 107
Lomita, California
Ardelyx Investigative Site 112
North Hollywood, California
Ardelyx Investigative Site 110
Northridge, California
Ardelyx Investigative Site 294
San Diego, California
Ardelyx Investigative Site 108
Thousand Oaks, California
Ardelyx Investigative Site 178
Cutler Bay, Florida
Ardelyx Investigative Site 131
Fort Lauderdale, Florida
Ardelyx Investigative Site 136
Hialeah, Florida
Ardelyx Investigative Site 130
Hialeah, Florida
Ardelyx Investigative Site 287
Homestead, Florida
Ardelyx Investigative Site 106
Miami, Florida
Ardelyx Investigative Site 127
Miami Lakes, Florida
Ardelyx Investigative Site 123
Miami Springs, Florida
Ardelyx Investigative Site 126
Pompano Beach, Florida
Ardelyx Investigative Site 132
Port Orange, Florida
Ardelyx Investigative Site 150
St. Petersburg, Florida
Ardelyx Investigative Site 254
West Palm Beach, Florida
Ardelyx Investigative Site 234
Athens, Georgia
Ardelyx Investigative Site 138
Atlanta, Georgia
Ardelyx Investigative Site 148
Atlanta, Georgia
Showing 40 of 111 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.